4th International Conference on Cardiomyopathy in Children
May 18-19, 2017
Bethesda North Marriott Hotel and Conference Center, MD

Thursday, May 18, 2017

7:30 am
**Continental Breakfast**

8:00 am – 8:30 am
Opening Remarks: Steven E. Lipshultz, MD and Lisa Yue, CCF founding executive director

8:30 am – 9:30 am
**Session 1: New Heart Failure Targets**
Session Leaders: Daphne Hsu, MD and Paul Kantor, MBBCh, DCH

- Mitochondrial remodeling
  Dan Bernstein, MD (Mayo Clinic)
- Neurohormonal targets: Entresto, Serelaxin, tolvaptan
  Robert Shaddy, MD (CHOP)
- Non-cardiac targets to treat heart failure in children: exercise, nutrition, anemia.
  Beth Kaufman, MD (Stanford)
- Panel Discussion

9:30 am – 10:40 am
**Session 2: Optimizing donor quality for pediatric heart transplantation**
Session Leaders: Steven Webber, MD and Michael Burch, MB ChB, MD

- Clinical and echocardiographic risk assessment of donor quality
  Anne Dipchand, MD (Hospital for Sick Children)
- Serum biomarkers of primary graft failure
  Charles Canter, MD (Washington University in St. Louis)
- Pharmacologic resuscitation of donors – old tricks, new twists
  Steve Webber, MBChB, MRCP (Vanderbilt University)
- Continuous donor perfusion for heart preservation
  Richard Kirk, MA MB BChir (Newcastle Upon Tyne)
- Panel Discussion

10:40 am – 10:50 am
**Break**

10:50 am – 11:50 am
**Session 3: Current controversies in diagnosis and management**
Session Leader: Steve Colan, MD

- Management and indications for transplant in restrictive cardiomyopathy
  Elizabeth Blume (Boston Children’s)
- Evidence concerning efficacy of exercise restriction in hypertrophic cardiomyopathy
  Mark Friedberg (RAND Corporation)
- Indications for primary prevention ICD implantation in children with hypertrophic cardiomyopathy
  Dominic Abrams, MD (Boston Children’s)
- Panel Discussion
11:50 am – 12:50 pm

Session 4: New cutting-edge topics that including studies/approaches leading to future pathophysiologic understanding of the diseases
Session Leader: Jeffrey Towbin, MD

- Scientific basis of overlapping syndromes: cardiomyopathy and arrhythmias.
  Jeffrey Towbin, MD (University of Tennessee)
- Scientific basis of overlapping syndromes: cardiomyopathy and congenital heart disease.
  Weinian Shou, PhD (Indiana University)
- New insights into hemato-onco-cardiology.
  Jean Ballweg, MD (University of Tennessee)
- Cardio-renal interactions and diseases.
- Genes and proteins: the mechanisms of cardiomyopathies.
  Jeffrey Saffitz, MD, PhD (Harvard)

12:50 pm – 1:50 pm

Lunch

1:50 pm – 3:10 pm

Session 5: State-of-the-art current knowledge
Session Leader: Melanie Everitt, MD and Robert Weintraub, MB.BS

- Age and Gender Differences in Response to Heart Failure Medications in Children: Evidence for What Works and Impact for Future Trials
  Carmen Sucharov, PhD (University of Colorado)
  Shelley Miyamoto, MD (University of Colorado)
- Risk Stratification in Pediatric Hypertrophic Cardiomyopathy: Insights for Bridging the Evidence Gap?
  Shaji Menon, MD (Primary Children's Hospital)
- Implantable Cardiac Defibrillators in Pediatric Hypertrophic Cardiomyopathy: Programming to Avoid Inappropriate Shocks—Should There be a Different Threshold for Primary vs. Secondary Prevention
  Anne Dubin, MD (Stanford)
- ICDs and Biventricular Pacing in Pediatric Dilated Cardiomyopathy: Preventing Death and Delaying Heart Transplant
  Charles Berul, MD (Children’s National)
- Exercise Training for Children with Cardiomyopathy
  Philip Thrush, MD (Lurie Children’s Hospital)
- Panel Discussion

3:10 pm – 3:20 pm

Break

3:20 pm – 5:25 pm

Young Investigator Abstracts
Moderator: James Wilkinson, MD

5:30 pm – 8:30 pm

Dinner

Friday, May 19, 2017

7:30 am

Continental Breakfast

8:00am – 8:50 am

Session 6: Update on ventricular assist devices and PumpKIN trial
Session Leader: Charles Canter, MD

- Pumpkin status
  William Mahle, MD (Emory)
- Contemporary trends in VAD us in pediatric dilated cardiomyopathy: insights from PEDIMACS
  David Rosenthal, MD (Stanford)
8:50 am – 10:00 am  
**Session 7: Gene-directed therapies**  
Session Leader: Wendy Chung, MD  
- Novel gene discoveries in pediatric cardiomyopathy:  
  Stephanie Ware, MD, PhD (Indiana University)  
  Teresa Lee, MD (Columbia)  
- Prevention of cardiomyopathy in genetically at-risk individuals  
  Carolyn Ho (Brigham and Women's Hospital)  
- Molecular treatment of genetic cardiomyopathies  
  Christine Seidman, MD (Harvard)  
- Panel Discussion

10:00 am – 10:10 am  
**Break**

10:10 am – 11:00 am  
**Session 8: Development of new translationally-derived diagnostic markers and new targeted therapies**  
Session Leader: John Lynn Jefferies, MD  
- The use of microRNAs in the diagnosis of heart failure  
  Jeffrey Robbins, PhD (CCHMC)  
Derived biomarkers panelists:  
  Michael Taylor, MD (Cincinnati Children’s)  
  Targeting protein kinase C: A novel paradigm for heart failure therapy  
  John Lynn Jefferies, MD (Cincinnati Children’s)  
New targeted therapies panelists:  
  Steven Colan, MD (Boston Children’s)

11:00 am – 11:45 am  
**Session 9: Pediatric Cardiomyopathy Registry biomarker and genetics studies**  
Session Speaker: James D. Wilkinson, MD, MPH

11:45 am – 12:45 pm  
**Lunch**

12:45 pm – 1:55 pm  
**Session 10: Designing reliable clinical microsystems centered around the needs of cardiomyopathy children and their families**  
*(Four 10-minute presentations and 30-minute panel discussion = 70 minutes)*  
Session Leader: Paul Barach, MD  
Presenters:  
- Helen Haskell, MA, IHI Board Member and President (Mothers Against Medical Errors)  
- Julie Johnson, PhD, (Feinberg School of Medicine, Northwestern University)  
- Lawrence C. Kleinman, MD, MPH, (Case Western)  
Panel Discussion

1:55 pm – 3:00 pm  
Conference Wrap Up: Steven E. Lipshultz, MD

3:00 pm  
Conference Adjournment